secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001558370-22-012517
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Q2 net loss $40.5M, down from $78.5M YoY; cash $231.8M
----------------------------------------------------------------------

- Net loss of $40.5M in Q2 2022 vs $78.5M in Q2 2021; six-month loss $109.5M vs $169.1M.
- R&D expenses $26.9M (Q2 2022) vs $44.9M (Q2 2021), down on cost-saving measures and UKONIQ withdrawal.
- Cash & investments $231.8M at June 30, 2022; expected to fund operations into H2 2023.
- PDUFA goal date for ublituximab in RMS set for December 28, 2022; preparing for potential early 2023 launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000155837022012517/0001558370-22-012517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000155837022012517/tgtx-20220808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-012517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer